Scancell Holdings Plc Directorate Changes (0930E)

TIDMSCLP

RNS Number : 0930E

Scancell Holdings Plc

26 October 2022

26 October 2022

Scancell Holdings plc

("Scancell" or the "Company")

Directorate Changes

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies, today announces that John Chiplin intends to resign his role as Executive Chairman and Non-Executive Director of the Company for personal reasons but is staying on for an interim period until a new Chair is appointed.

The Board has initiated a formal search for a new Chair and a further announcement regarding details and timings will be made in due course.

The Board also announces that Richard Goodfellow intends to retire as Non-Executive Director of the Company and will not seek re-election at the upcoming AGM.

The Board also confirms that they have appointed Susan Clement Davies, an independent Non-Executive Director and Chair of the Audit Committee, as Deputy Chair.

Prof Lindy Durrant, Chief Executive Officer, Scancell , commented: "The Board wishes to express its sincere thanks to John for his excellent stewardship, support and enthusiasm throughout his tenure as Executive Chairman. We are pleased that he will be with us for a while longer.

"The Board also wishes to express its gratitude to Richard. As Scancell's co-founder and until 2017 its CEO Richard has been instrumental in Scancell's evolution. His unfailing support and vision has been an inspiration to everyone involved at Scancell. We wish Richard a long and happy retirement."

Dr John Chiplin, Executive Chairman, Scancell, commented : " It has been a privilege and pleasure to have chaired the Scancell Board over the last six years. As I plan to hand over the reins to a successor, I will be leaving the Company well financed, with an exciting product pipeline, a strong management team and a high-quality shareholder base. I certainly will continue to remain a supportive shareholder."

Dr Richard Goodfellow, Non-Executive Director, Scancell, commented : " Scancell was founded over 20 years ago from Lindy's innovative and visionary research and it has been a privilege to have been involved in the evolution of the Company from a few highly original ideas to an established biotechnology company with three products in clinical trials and its first commercially significant deal. I remain hugely optimistic about the future of the Company and I am sure that the best is yet to come ."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 
 For further information, please contact: 
 
 Scancell Holdings plc                                    [phone] 
 Dr John Chiplin, Executive Chairman 
 Professor Lindy Durrant, CEO 
 Stifel Nicolaus Europe Limited (Nominated 
  Adviser and Joint Broker) 
  Nicholas Moore/Samira Essebiyea/William Palmer-Brown 
  (Healthcare Investment Banking) 
  Nick Adams/Nick Harland (Corporate Broking)             [phone] 
 
 Panmure Gordon (UK) Limited (Joint Broker)               [phone] 
 Freddy Crossley/Emma Earl (Corporate Finance) 
 Rupert Dearden (Corporate Broking) 
 FTI Consulting                                           [phone] 
 Simon Conway/Rob Winder/Alex Davis 
 

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope (R) and ImmunoBody (R) for vaccines and GlyMab(R) and AvidiMab (R) for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope (R) and ImmunoBody (R) ) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab(R) ) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab (R) ).

For further information about Scancell, please visit: https://www.scancell.co.uk/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABKPBDOBDDBKB

(END) Dow Jones Newswires

October 26, 2022 02:00 ET (06:00 GMT)